Illumina, Inc. (ILMN)
Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience while we got started.
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.
Here's Why Illumina (ILMN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ILMN vs. ALNY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Illumina Stock Got Mashed on Monday
On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.
Illumina (ILMN) International Revenue Performance Explored
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability
Illumina restored its profitability well: Free Cash Flow is reaching elevated levels. However, the placement of ILMN in China's unreliable entity list could have disruptive implications for its operations in the country. The maximum exposure is 7% of its sales, which is manageable.
Why Illumina Stock Is Sinking Today
Shares of Illumina (ILMN -8.97%) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m.
Illumina Analysts Slash Their Forecasts Following Q4 Results
Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.
ILMN Q4 Earnings Miss Estimates, Stock Dips in Aftermarket
Illumina's fourth-quarter revenues from the consumables business show robust growth.
Illumina, Inc. (ILMN) Q4 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Conor McNamara - RBC Capital Markets Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies David Westenberg - Piper Sandler Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Patrick Donnelly - Citi Operator Good day, ladies and gentlemen and welcome to the Fourth Quarter 2024 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
